These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 8183469)

  • 1. Dietary factors in the management of Parkinson's disease.
    Kempster PA; Wahlqvist ML
    Nutr Rev; 1994 Feb; 52(2 Pt 1):51-8. PubMed ID: 8183469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of a controlled low-protein diet on the pharmacological response to levodopa and on the plasma levels of L-dopa and amino acids in patients with Parkinson's disease].
    Sanchís G; Mena MA; Martín del Río R; Morales B; Casarejo MJ; de Yébenes MJ; Tabernero C; Jiménez A; de Yébenes JG
    Arch Neurobiol (Madr); 1991; 54(6):296-302. PubMed ID: 1811460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy?
    Mercuri NB; Bernardi G
    Trends Pharmacol Sci; 2005 Jul; 26(7):341-4. PubMed ID: 15936832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pulmonary formulation of L-dopa enhances its effectiveness in a rat model of Parkinson's disease.
    Bartus RT; Emerich D; Snodgrass-Belt P; Fu K; Salzberg-Brenhouse H; Lafreniere D; Novak L; Lo ES; Cooper T; Basile AS
    J Pharmacol Exp Ther; 2004 Aug; 310(2):828-35. PubMed ID: 15039453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment strategies in Parkinson's disease after a quarter century experiences with L-DOPA therapy.
    Fischer PA
    J Neural Transm Suppl; 1995; 46():381-9. PubMed ID: 8821073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease.
    Cools R
    Neurosci Biobehav Rev; 2006; 30(1):1-23. PubMed ID: 15935475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inter- and intra-individual variation in L-dopa pharmacokinetics in the treatment of Parkinson's disease.
    Nomoto M; Nishikawa N; Nagai M; Yabe H; Nakatsuka A; Moritoyo H; Moritoyo T; Kubo M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S21-4. PubMed ID: 19131037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levodopa: pharmacology, pharmacokinetics, and pharmacodynamics.
    Juncos JL
    Neurol Clin; 1992 May; 10(2):487-509. PubMed ID: 1584186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levodopa in the early treatment of Parkinson's disease.
    Murata M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. L-dopa treatment and Parkinson's disease.
    Lees AJ
    Q J Med; 1986 Jun; 59(230):535-47. PubMed ID: 3529159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The results of drug holiday in Parkinson's disease].
    Martínez F; Castillo J; Castro A; Lema M; Noya M
    Neurologia; 1992 Nov; 7(9):254-9. PubMed ID: 1445710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
    Henchcliffe C; Schumacher HC; Burgut FT
    Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What has been learnt from study of dopamine receptors in Parkinson's disease?
    Hurley MJ; Jenner P
    Pharmacol Ther; 2006 Sep; 111(3):715-28. PubMed ID: 16458973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opioids and motor complications in Parkinson's disease.
    Samadi P; Bédard PJ; Rouillard C
    Trends Pharmacol Sci; 2006 Oct; 27(10):512-7. PubMed ID: 16908075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis.
    Merello M; Nouzeilles MI; Arce GP; Leiguarda R
    Mov Disord; 2002 Jul; 17(4):795-8. PubMed ID: 12210878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical effects of chronic L-dopa treatment in rats: implications for emergence of tolerance phenomena in patients with Parkinson's disease.
    Melamed E; Globus M; Rosenthal J; Uzzan A
    Adv Neurol; 1987; 45():507-10. PubMed ID: 3825730
    [No Abstract]   [Full Text] [Related]  

  • 18. Microbial endocrinology as a basis for improved L-DOPA bioavailability in Parkinson's patients treated for Helicobacter pylori.
    Lyte M
    Med Hypotheses; 2010 May; 74(5):895-7. PubMed ID: 19962247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].
    Hironishi M; Miwa H; Kondo T
    No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Intravenous infusion of L-dopa: current prospective therapies].
    Peppe A; De Angelis D; Tolli VS; Rizzo PA; Scoppetta C
    Riv Neurol; 1991; 61(5):197-200. PubMed ID: 1808680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.